WO1999014366A3 - Detection of minimal residual disease in lymphoid malignancies - Google Patents

Detection of minimal residual disease in lymphoid malignancies Download PDF

Info

Publication number
WO1999014366A3
WO1999014366A3 PCT/NL1998/000542 NL9800542W WO9914366A3 WO 1999014366 A3 WO1999014366 A3 WO 1999014366A3 NL 9800542 W NL9800542 W NL 9800542W WO 9914366 A3 WO9914366 A3 WO 9914366A3
Authority
WO
WIPO (PCT)
Prior art keywords
minimal residual
nucleic acid
residual disease
detection
lymphoid malignancies
Prior art date
Application number
PCT/NL1998/000542
Other languages
French (fr)
Other versions
WO1999014366A2 (en
Inventor
Dongen Jacobus Johannes Ma Van
Martha Jacoba Pongers-Willemse
Original Assignee
Univ Erasmus
Dongen Jacobus Johannes Maria
Pongers Willemse Martha Jacoba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Erasmus, Dongen Jacobus Johannes Maria, Pongers Willemse Martha Jacoba filed Critical Univ Erasmus
Priority to EP98944341A priority Critical patent/EP1015635A2/en
Priority to CA002303945A priority patent/CA2303945A1/en
Priority to AU91900/98A priority patent/AU9190098A/en
Publication of WO1999014366A2 publication Critical patent/WO1999014366A2/en
Publication of WO1999014366A3 publication Critical patent/WO1999014366A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention relates to the field of cancer diagnosis, more specific to the monitoring of disease development during and after treatment. The invention comprises a method for determining minimal residual disease comprising amplifying nucleic acid molecules using at least one primer reactive with a common gene segment and further comprising identifying malignancy-specific nucleic acid sequences by hybridising with a fluorogenic probe specifically and selectively reactive with said malignancy-specific nucleic acid sequences.
PCT/NL1998/000542 1997-09-18 1998-09-18 Detection of minimal residual disease in lymphoid malignancies WO1999014366A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP98944341A EP1015635A2 (en) 1997-09-18 1998-09-18 Detection of minimal residual disease in lymphoid malignancies
CA002303945A CA2303945A1 (en) 1997-09-18 1998-09-18 Detection of minimal residual disease in lymphoid malignancies
AU91900/98A AU9190098A (en) 1997-09-18 1998-09-18 Detection of minimal residual disease in lymphoid malignancies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP97202858 1997-09-18
EP97202858.3 1997-09-18

Publications (2)

Publication Number Publication Date
WO1999014366A2 WO1999014366A2 (en) 1999-03-25
WO1999014366A3 true WO1999014366A3 (en) 1999-05-06

Family

ID=8228734

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL1998/000542 WO1999014366A2 (en) 1997-09-18 1998-09-18 Detection of minimal residual disease in lymphoid malignancies

Country Status (4)

Country Link
EP (1) EP1015635A2 (en)
AU (1) AU9190098A (en)
CA (1) CA2303945A1 (en)
WO (1) WO1999014366A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019284210A1 (en) * 2018-06-11 2021-01-07 Monoquant Pty Ltd Amplification method

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015600A1 (en) * 1990-03-30 1991-10-17 City Of Hope Detection of minimal residual disease in lymphoid malignancies
WO1992009702A1 (en) * 1990-11-28 1992-06-11 University Of Texas System Board Of Regents Methods and compositions for detecting and quantitating hematopoietic tumors
US5538848A (en) * 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
WO1996034983A1 (en) * 1995-05-05 1996-11-07 The Perkin-Elmer Corporation Methods and reagents for combined pcr amplification and hybridization probing assay
WO1997005278A1 (en) * 1995-07-27 1997-02-13 Dalgety Plc Methods for determining the coat colour genotype of a pig

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991015600A1 (en) * 1990-03-30 1991-10-17 City Of Hope Detection of minimal residual disease in lymphoid malignancies
WO1992009702A1 (en) * 1990-11-28 1992-06-11 University Of Texas System Board Of Regents Methods and compositions for detecting and quantitating hematopoietic tumors
US5538848A (en) * 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
WO1996034983A1 (en) * 1995-05-05 1996-11-07 The Perkin-Elmer Corporation Methods and reagents for combined pcr amplification and hybridization probing assay
WO1997005278A1 (en) * 1995-07-27 1997-02-13 Dalgety Plc Methods for determining the coat colour genotype of a pig

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BEISHUIZEN ET AL.: "MOLECULAR BIOLOGY OF ACUTE LYMPHOBLASTIC LEUKEMIA: IMPLICATIONS FOR DETECTION OF MINIMAL RESIDUAL DISEASE", ACUTE LEUKEMIAS V, 1996, pages 460 - 474, XP002095128 *
CALLAGHAN ET AL.: "CHARACTERISATION OF K-ras MUTATIONS BY A NON GEL-BASED PROCEDURE COMBINING ARMS PRIMER EXTENSION AND TaqMan", AM. J. OF HUM. GEN., vol. 61, no. 4 Suppl., 28 October 1997 (1997-10-28), pages A62/332, XP002070264 *
GELMINI ET AL.: "QUANTITATIVE POLYMERASE CHAIN REACTION-BASED HOMOGENEOUS ASSAY WITH FLUOROGENIC PROBES TO MEASURE c-erbB-2 ONCOGENE AMPLIFICATION", CLIN. CHEMISTRY, vol. 43, no. 5, May 1997 (1997-05-01), pages 752 - 758, XP002070263 *
GERARD ET AL.: "IMPROVED QUANTITATION OF MINIMAL RESIDUAL DISEASE IN MULTIPLE MYELOMA USING REAL-TIME POLYMERASE CHAIN REACTION AND PLASMID-DNA COMPLEMENTARITY DETERMINING REGION III STANDARDS", CANCER RESEARCH, vol. 58, 1 September 1998 (1998-09-01), pages 3957 - 3964, XP002095189 *
GIBSON U E M ET AL: "A NOVEL METHOD FOR REAL TIME QUANTITATIVE RT-PCR", GENOME RESEARCH, vol. 6, no. 10, October 1996 (1996-10-01), pages 995 - 1001, XP000642796 *
HEID C A ET AL: "REAL TIME QUANTITATIVE PCR", GENOME RESEARCH, vol. 6, no. 10, October 1996 (1996-10-01), pages 986 - 994, XP000642795 *
LANG R ET AL: "A rapid method for semiquantitative analysis of the human Vbeta -repertoire using TaqManPCR", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 203, no. 2, 25 April 1997 (1997-04-25), pages 181-192, XP004059583 *
LEE L G ET AL: "ALLELIC DISCRIMINATION BY NICK-TRANSLATION PCR WITH FLUOROGENIC PROBES", NUCLEIC ACIDS RESEARCH, vol. 21, no. 16, 11 August 1993 (1993-08-11), pages 3761 - 3766, XP000470188 *

Also Published As

Publication number Publication date
WO1999014366A2 (en) 1999-03-25
EP1015635A2 (en) 2000-07-05
AU9190098A (en) 1999-04-05
CA2303945A1 (en) 1999-03-25

Similar Documents

Publication Publication Date Title
WO2000077260A8 (en) Genomic profiling: a rapid method for testing a complex biological sample for the presence of many types of organisms
FR2755149B1 (en) METHOD FOR DIAGNOSING GENETIC DISEASES BY MOLECULAR COMBING AND DIAGNOSTIC KIT
EP0357336A3 (en) Method for detection of specific nucleic acid sequences
AU2001254794A1 (en) Diagnosis of diseases associated with dna adducts
FI953445A0 (en) Procedure for Sensitive Detection of Nucleic Acids
FI950487A (en) Method, reagent and test kit for detecting and amplifying nucleic acid sequences
EP0774518A3 (en) Nucleic acid probes complementary to Human Papillomavirus nucleic acid and related methods and kits
EP1201771A3 (en) Detection and identification of human papillomavirus by PCR and type-specific reverse hybridization
WO2002079411A3 (en) Microarray gene expression profiling in clear cell renal cell carcinoma: prognosis and drug target identification
WO2000024929A3 (en) Linear amplification mediated pcr (lam pcr)
WO2003060163A3 (en) Discrimination and detection of target nucleotide sequences using mass spectrometry
CA2039517A1 (en) Dna probe signal amplification
EP0714987A3 (en) Method for quantifying genomic DNA
EP1734134A3 (en) A novel, prostate-specific gene for diagnosis, prognosis and management of prostate cancer
WO2001057237A3 (en) Methods employing increased dye-fluorescence upon nitroreduction
NZ521988A (en) Polyamide nucleic acid derivatives, agents and methods for producing them
WO2003052135A8 (en) Method and nucleic acids for the analysis of a lung cell proliferative disorder
WO1998014611A3 (en) Detection and identification of non-polio enteroviruses
WO2004043232A3 (en) Methods for identifying risk of melanoma and treatments thereof
WO1997022721A3 (en) Cancer detection probes
WO2003014388A3 (en) Method and nucleic acids for the analysis of colon cancer
AU2135497A (en) Genetic markers and methods for the detection of escherichia coli serotype-0157:h7
WO2005027710A3 (en) Methods for identifying subjects at risk of melanoma and treatments thereof
WO1999066075A3 (en) Diagnostic method based on quantification of extramitochondrial dna
SG153624A1 (en) Isometric primer extension method and kit for detection and quantification of specific nucleic acid

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2303945

Country of ref document: CA

Ref country code: CA

Ref document number: 2303945

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 09528453

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1998944341

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1998944341

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1998944341

Country of ref document: EP